Expanding NavaX adoption, new Top Pharma wins, and continued global growth signal accelerating shift toward operational AI 

Boston, Massachusetts – April 23, 2026 – ArisGlobal, an AI-first technology company at the forefront of life sciences and creator of LifeSphere®, today announced strong momentum in the first quarter of 2026, driven by expanding enterprise adoption of NavaX™, significant new customer wins, and broad-based growth across its global customer base. As life sciences organizations move from AI experimentation to enterprise-scale operationalization, ArisGlobal is seeing accelerating demand for proven, production-ready AI embedded directly into real-world workflows. 

Customer Growth and Strength 

Demand for LifeSphere accelerated in Q1 2026, with approximately 120% year-over-year bookings growth. Notably, 26% of existing customers expanded their LifeSphere footprint, and six new customers selected NavaX AI—clear signals of strong platform confidence and increasing reliance on AI-enabled capabilities to manage rising data volumes and regulatory complexity. 

New customer wins and expansions in the quarter alone, include: 

• Six new NavaX AI customers, across North America, Europe, and Asia Pacific 

• Two net new core LifeSphere platform customers, including a Top 50 Pharma 

• Three Top 10 and 15 Top 50 pharmaceutical companies expanded their LifeSphere footprint – demonstrating continued traction among the industry’s largest and most complex organizations 

NavaX powers a growing range of real-world applications across pharmacovigilance — from case intake and coding to signal detection, document generation, and multilingual processing — enabling organizations to reduce manual effort, accelerate timelines, and improve data quality and compliance. Recent highlights include a Top 10 global pharma expanding NavaX Dynamic Data Extraction for high-volume case processing, another Top 10 pharma advancing AI-powered Literature Intelligence to improve safety workflow automation, and a Top 50 pharma deepening NavaX adoption to support more connected safety and regulatory operations. 

“LifeSphere and NavaX were built for exactly this moment — when the pressure to do more, faster, and with greater precision has never been higher,” shared Steve Nuckols, Chief Customer Officer at ArisGlobal. “Our customers aren’t just adopting the platform; they’re gaining a proven AI foundation that scales with their ambitions and delivers measurable impact from the start.” 

Product Innovation 

ArisGlobal continued to expand its AI-driven product portfolio in Q1, introducing new AI products designed to further automate and enhance safety and regulatory workflows. Key highlights include: 

• Introduction of XDI, a next-generation data intelligence cortex enabling more unified, explainable decision-making across R&D functions 

• Three new NavaX Agents: Signals Agents, Distribution Agents, and Intelligence Agents. Within six weeks of announcing the new NavaX Agents, a Top 20 pharma has already subscribed to Signals and Distributions Agents. 

• Introduction of NavaX Translation, enabling faster, more scalable multilingual pharmacovigilance through embedded AI-driven translation 

• The launch of ReporterX, accelerating AI-driven collection of patient data at the point of capture 

“Our investment in AI is accelerating — and so are the results our customers are seeing,” said Ann-Marie Orange, CIO and Global Head of R&D at ArisGlobal. “From NavaX to XDI, we’re bringing proven, production-ready capabilities to market at a pace that delivers real, measurable impact across R&D and pharmacovigilance workflows.”  

“The industry has moved past the question of whether to adopt AI — the question now is how fast and how deep. With NavaX operationalizing AI across pharmacovigilance workflows and XDI bringing unified intelligence to R&D decision-making, ArisGlobal is giving our customers the tools to lead that shift — not just respond to it,” shared Aman Wasan, CEO at ArisGlobal.